Citations

Clear

75 citation(s) found for "Starlinger, P".

International Reference Values for Surgical Outcomes of Total Pancreatectomy
Berchtold, Caroline , Kuemmerli, Christoph, Li, Zhihao , Eden, Janina , Wu, Pengfei , Cecchetto, Sara Nicole, Kendrick, Michael L. , Pecorelli, Nicolò , Guarneri, Giovanni , Farooqui, Waqas , Tschuor, Christoph , Burgdorf, Stefan Kobbelgaard , Mühlhäusser, Julia , Gass, Jörn‐Markus , Koh, Ye-Xin, Seip, Tomas, Santibañes, Martín de , Todeschini, Letizia , Marchegiani, Giovanni, Belfil, Nadiya , Boggi, Ugo, Cappelle, Marie , Koerkamp, Bas Groot , Dutkowski, Philipp , Hackert, Thilo , Truty, Mark J. , Group, Outcomes for Total Pancreatectomy, Valle, Valentina , Giulianotti, Pier Cristoforo , Pessaux, Patrick, Thapa, Prabin , Kuzman, Matta , Pandanaboyana, Sanjay, He, Jin , Kendrick, Michael, Truty, Mark, Li, Zhihao , Groot Koerkamp, Bas , Müller, Philip C , Breuer, Eva , Vallorani, Alessia , Hansen, Carsten Palnæs , Guidetti, Cristiano , Campbell, Brady A. , Cecchetto, Sara Nicole, Gudmundsdottir, Hallbera , Starlinger, Patrick , Goh, Brian K P , Koh, Ye-Xin , Rebelo, Artur , Kleeff, Jorg H. , Marchegiani, Giovanni , Lesurtel, Mickaël , Machado, Marcel Autran C. , Kauffmann, Emanuele F. , Benedetto, Fabrizio Di , Roberts, Keith John , Nevler, Avinoam , Lavu, Harish , Nickel, Felix , He, Jing , Falconi, Massimo , Billeter, Adrian T. , Müller-Stich, Beat Peter , Group, Outcomes for Total Pancreatectomy, Halle-Smith, James Michael , Giannone, Fabio , Pessaux, Patrick , Sánchez‐Velázquez, Patricia , Maharjan, Dhiresh Kumar , Torres, Orlando Jorge Martins

Mayo Clinic

JAMA Surgery | November 12, 2025 | Volume: 161 | Issue: 1 | Pages: 50

10.1001/jamasurg.2025.4941 | PMID 41222926 Get It

Importance Total pancreatectomy (TP) is indicated for advanced pancreatic cancer or multifocal tumors. Furthermore, TP may be performed to avoid the risk of pancreatic fistula in selected patients to improve the perioperative risk profile. Objective To define reference values for TP based on a low-risk cohort treated at expert centers. Design, Setting, and Participants This multicenter study analyzed outcomes from patients undergoing primary TP for malignant or benign lesions from 25 international expert centers from January 2017 to November 2023. Low-risk patients undergoing TP (LR-TP) were without vascular resections or significant comorbidities. Exposures TP. Main Outcomes and Measures Twenty reference values were derived from the 75th or the 25th percentile of the median values of all centers. Outcomes of LR-TP were compared with a cohort of TP with vascular resection, TP due to high-risk pancreatic anastomosis, and the benchmark values for low-risk pancreatoduodenectomy. Results Of 994 patients, 333 (33.5%; median [IQR] age, 66 [58-72] years; 171 male [51.4%]) qualified as the LR-TP cohort. Reference values included blood loss (≤1000 mL), major complications (≤37%), 3-month postoperative mortality (<6%), and retrieved lymph nodes (≥29). Compared with TP with vascular resections, reference cutoffs were not met for major complications (51% vs LR-TP ≤37%) and 90-day mortality (11% vs LR-TP ≤6%). For TP due to high-risk anastomosis, failure to rescue rate (38% vs ≤6%) and 90-day mortality (11% vs LR-TP ≤6%) were not met. Compared with pancreatoduodenectomy, reference values for postoperative mortality were 3 times higher for LR-TP (≤2% vs ≤6%) and less for resected lymph nodes (≥16 vs ≥29). Conclusions and Relevance This case-control study provided global reference values for TP, indicating significantly higher postoperative morbidity and mortality compared with pancreatoduodenectomy. Perioperative morbidity of TP was especially increased in patients with vascular resections. These reference values can serve for quality control of pancreatic surgery.
Evolution of the Indications and Outcomes of Total Pancreatectomy
Antwi, Stella K Adjei, Warner, Susanne G, Smoot, Rory L. , Kendrick, Michael L. , Truty, Mark J. , Smoot, Rory L , Gudmundsdottir, Hallbera , Thiels, Cornelius A. , Warner, Susanne G. , Starlinger, Patrick

Mayo Clinic

Journal of the American College of Surgeons | November 6, 2025 | Volume: 242 | Issue: 2 | Pages: 259-270

10.1097/xcs.0000000000001642 | PMID 41195873 Get It

BACKGROUND: The first total pancreatectomy (TP) resulting in survival past the immediate postoperative period was performed at Mayo Clinic in 1944. Although still uncommonly performed, indications have recently fluctuated. We aimed to evaluate trends in TP use and outcomes over four decades. STUDY DESIGN: Patients who underwent single-stage TP at Mayo Clinic Rochester from 1988 to 2024 were analyzed in two cohorts: early era (EE, 1988 to 2009) and modern era (ME, 2010 to 2024). RESULTS: In total, 437 patients were identified: 118 during EE (mean 8 per year) and 319 during ME (mean 21 per year). Primary indications were adenocarcinoma (42% EE vs 60% ME), intraductal papillary mucinous neoplasm (31% EE vs 17% ME), and chronic pancreatitis (11% EE vs 13% ME; p < 0.001). Concurrent vascular resection was performed in 9.3% (EE; all venous only) vs 53% (ME; venous alone in 20% and arterial with or without venous in 33%; p < 0.001). Multivisceral resection was performed in <1% (EE) vs 24% (ME; p < 0.001). Major complications occurred in 13% (EE) vs 27% (ME; p = 0.018), and 90-day mortality was 3.4% (EE) vs 6.3% (ME; p = 0.35). For adenocarcinoma, 5-year median overall survival from both surgery and diagnosis was significantly improved in ME (p = 0.009 and p < 0.001, respectively). Median last HbA1c was 7.7 (EE) vs 7.3 (ME; p < 0.001). Among patients surviving more than 1 year, insulin pumps were used in 12% (EE) vs 49% (ME; p < 0.001). Conclusions: The use of TP has dramatically increased in recent years, primarily for adenocarcinoma alongside increased use of neoadjuvant therapy and ever-expanding criteria for anatomic resectability. Operative complexity has significantly increased with resultant increased perioperative morbidity. TP remains a higher-risk procedure, specifically with en bloc vascular resections, emphasizing the importance of appropriate patient selection, preoperative patient education, and thoughtful postoperative and long-term management.
Reply: Dropout dynamics in RT+LT vs LR for pCCA—An overlooked variable?
Dong, Yawen , Li, Zhihao , Gores, Gregory J. , Heimbach, Julie K. , Taner, Timuçin , Starlinger, Patrick , Gores, Gregory J. , Taner, Timucin , Starlinger, Patrick , Li, Zhihao , Heimbach, Julie K , Dong, Yawen , Smoot, Rory L.

Mayo Clinic

Hepatology | October 2, 2025 | Volume: 83 | Issue: 5 | Pages: E151-E152

10.1097/hep.0000000000001556 | PMID 41037682 Get It

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Kournoutas, Ioannis , Marell, Paulina S. , Peersen, Anina, Shah, Priyanshi , VanDommelen, Kyle, Gupta, Garima , Akce, Mehmet , Yang, Ju Dong , Chen, Pin‐Jung , Naleid, Nikolas , Peterson, Nicole , Sahai, Vaibhav , Halfdanarson, Thorvardur, Kankeu, Lionel Fonkoua, Washburn, Leslie, Conboy, Caitlin B. , Goenka, Ajit H. , Thompson, Scott A. , Ahn, Daniel H. , Jatoi, Aminah , Marell, Paulina, Gile, Jennifer , Yang, Ju Dong , Sahai, Vaibhav , Jin, Zhaohui , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A, Goenka, Ajit, Starlinger, Patrick , Roberts, Lewis, Jatoi, Aminah , Ou, Fang-Shu , Tran, Nguyen , Conboy, Caitlin B , Kamath, Suneel Deepak , Mahipal, Amit , Wee, Wen , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Torbenson, Michael , Thompson, Scott, Venkatesh, Sudhakar K. , Starlinger, Patrick , Roberts, Lewis R. , Gores, Gregory J. , Babiker, Hani M. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , McWilliams, Robert R. , Ou, Fang‐Shu

Mayo Clinic

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 11 | Pages: No page available

10.1093/oncolo/oyaf286 | PMID 40973475 Get It

Abstract Background Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab/bevacizumab (atezo/bev) and durvalumab/tremelimumab (durva/treme); however, there is a lack of comparative data. Methods We reviewed outcomes of patients with uHCC who initiated atezo/bev or durva/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan–Meier and Cox models, adjusting for baseline characteristics. Results Four hundred fifty-two uHCC pts were included. Median age: 68 years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo/bev (56%) and durva/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P = .66]; median TTD [m]: 4.9 vs 3.9 [P = .42] for atezo/bev vs durva/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P &lt; .001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P &lt; .001). Conclusions In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.
Reply: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma
Dong, Yawen , Li, Zhihao , Gores, Gregory J. , Heimbach, Julie K. , Smoot, Rory L. , Taner, Timuçin , Starlinger, Patrick , Gores, Gregory J. , Starlinger, Patrick , Smoot, Rory L , Li, Zhihao , Heimbach, Julie K , Dong, Yawen

Mayo Clinic

Hepatology | September 10, 2025 | Volume: 83 | Issue: 5 | Pages: E135-E136

10.1097/hep.0000000000001521 | PMID 40928305 Get It

Outcomes of palliative porto-mesenteric venous stenting in unresectable pancreatic malignancies
Antwi, S.K. Adjei, Halfdanarson, Thor R, Kendrick, Michael L. , Warner, Susanne G, Starlinger, Patrick P, Truty, Mark J. , Andrews, James C. , Fleming, Chad J. , Adjei Antwi, Stella Konadu , Zironda, Andrea , Fogliati, Alessandro, Truty, Mark J , Fogliati, Alessandro , Fiorentini, Guido , Warner, Susanne G. , Thiels, Cornelius A. , Starlinger, Patrick , Thompson, Scott M.

Mayo Clinic

The Oncologist | September 2, 2025 | Volume: 30 | Issue: 9 | Pages: No page available

10.1093/oncolo/oyaf267 | PMID 40891896 Get It

Abstract Importance and Objective Pancreatic cancer can lead to severe stenosis of the portomesenteric venous (PV/SMV) confluence due to extrinsic compression or direct invasion. This can result in venous hypertension associated with post-prandial abdominal pain, gastrointestinal bleeding, and ascites. In patients with unresectable tumors, transhepatic PV/SMV stenting has been reported; however, its safety and efficacy are poorly understood. Design, Setting and Participants All unresectable pancreatic cancer patients referred to Interventional Radiology to undergo palliative transhepatic PV/SMV stenting (2011–2024) were collected. Patient demographics, CT scans, transhepatic venograms, and clinical outcomes were reviewed. Intervention, Main Outcomes and Results In total, 129 patients were included; 92% had pancreatic ductal adenocarcinoma. Tumors were unresectable due to unreconstructable vascular involvement, metastatic disease, or poor performance status. Nearly 81% were symptomatic, while the remaining 24 asymptomatic patients presented with significant venous hypertensive varices and collaterals on imaging. Complete venous occlusion was seen in 39% of patients at the PV, the SMV, or the PV/SMV confluence; 97% of procedures were successful, with 4 technical failures at obtaining distal venous wire access. Adverse events occurred in 4 patients. Radiological follow-up was available in 94% of patients. Post-procedural primary stent patency was 80% at a median follow-up time of 20 months. Follow-up was available in 102 of the 105 symptomatic patients, with 85% reporting an improvement in symptoms. Conclusions and Relevance Palliative transhepatic PV/SMV stenting is a technically feasible and safe procedure in well-selected patients. Symptoms improvement can be seen in most patients. High-volume centers should consider this technique for patients with unresectable tumors who present with symptomatic stenosis or short segment occlusion.
Reply: The treatment options for de novo perihilar cholangiocarcinoma require more details
Dong, Yawen , Li, Zhihao , Gores, Gregory J. , Heimbach, Julie K. , Smoot, Rory L. , Taner, Timuçin , Starlinger, Patrick , Gores, Gregory J. , Starlinger, Patrick , Smoot, Rory L , Li, Zhihao , Heimbach, Julie K , Dong, Yawen

Mayo Clinic

Hepatology | August 13, 2025 | Volume: 83 | Issue: 5 | Pages: E139-E140

10.1097/hep.0000000000001497 | PMID 40802889 Get It

Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma
Dong, Yawen , Li, Zhihao , Podrascanin, V. , Eaton, John E. , Ilyas, Sumera I. , Gores, Gregory J. , Warner, Susanne G. , Diwan, Tayyab S. , Nagorney, David M. , Heimbach, Julie K. , Smoot, Rory L. , Taner, Timuçin , Gores, Gregory J. , Starlinger, Patrick , Smoot, Rory L , Ilyas, Sumera Irie , Warner, Susanne G , Li, Zhihao , Heimbach, Julie K , Dong, Yawen , Starlinger, Patrick

Mayo Clinic

Hepatology | July 7, 2025 | Volume: 83 | Issue: 5 | Pages: 1128-1142

10.1097/hep.0000000000001449 | PMID 40622853 Get It

Background and Aims: The optimal treatment strategy for de novo perihilar cholangiocarcinoma (pCCA) remains debated. This study compares outcomes between liver transplantation following neoadjuvant chemoradiation (RT+LT) and liver resection (LR), with (LR+VR) and without vascular resection (LR w/o VR). Approach and Results: This single-center, retrospective study included patients with de novo perihilar cholangiocarcinoma treated at the Mayo Clinic Rochester (1993–2023) with curative-intent surgery. Patients underwent either (1) LR, classified as LR+VR or LR w/o VR, or (2) RT+LT following the transplant protocol. Overall survival (OS) and recurrence-free survival were analyzed using as-treated and intention-to-treat approaches, incorporating competing risk analysis and direct matching. In the as-treated analysis, RT+LT showed superior median OS compared with LR w/o VR (78.0 vs. 58.2 mo, p =0.03) and LR+VR (25.8 mo, p <0.001). Considering dropout rates (RT+LT: 41%, LR: 28%), intention-to-treat analysis showed no significant OS difference between LR and RT + LT (31.7 vs. 38.5 mo, p =0.19). In matched as-treated analysis, RT + LT had no significant survival benefit over LR w/o VR (50.6 vs. 140.6 mo, p =0.08) or LR+VR (25.8 mo, p =0.11). Perioperative mortality was 4% (RT+LT), 7% (LR w/o VR), and 8% (LR + VR). Conclusions: Both LR and RT+LT achieve excellent oncological outcomes in selected patients with de novo perihilar cholangiocarcinoma. Key challenges remain dropouts during neoadjuvant therapy in patients planned for LT and high perioperative mortality for patients undergoing LR. OS doubles in patients undergoing LR+VR compared with dropouts, supporting LR+VR as a viable option for patients who are ineligible for LT. Appropriate patient selection is crucial, as those not undergoing surgery suffer from a dismal prognosis.
Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure—A multivariable model with APRI+ALBI
Dong, Yawen , Gregory, Lindsey A., Podrascanin, V. , Ammann, M. , Hackl, Hubert , Li, Zhihao , Starlinger, Johannes, Truty, Mark J. , Warner, Susanne G, Smoot, Rory L. , Nagorney, David M. , Podrascanin, Vanja , Santol, Jonas , Ammann, Markus , Pereyra, David , Hackl, Hubert , Li, Zhihao , Warner, Susanne G , Gruenberger, Thomas , Nagorney, David M , Starlinger, Patrick , Smoot, Rory L , Truty, Mark J , Dong, Yawen , Santol, Jonas , Pereyra, David , Starlinger, Johannes, Warner, Susanne G.

Mayo Clinic

Liver Transplantation | July 3, 2025 | Volume: 31 | Issue: 12 | Pages: 1450-1463

10.1097/lvt.0000000000000676 | PMID 40607909 Get It

Portal hypertension is a key factor in posthepatectomy liver failure (PHLF). While preoperative liver function tests like APRI+ALBI assess liver function, they only partially reflect portal hypertension severity. Elevated von Willebrand factor antigen (vWF-Ag) indicates endothelial dysregulation and correlates with portal hypertension. Combining vWF-Ag with APRI+ALBI may enhance PHLF prediction. A total of 534 patients who underwent liver resection at Mayo Clinic Rochester (2020–2024) were analyzed for PHLF incidence, postoperative morbidity, and 90-day mortality. Predictive probability for PHLF was assessed using receiver operating characteristic analysis and validated in an external Austrian cohort of 283 patients (2008–2017). vWF-Ag was then integrated into the existing APRI+ALBI multivariable model. PHLF grade B/C was reported in 56 patients (10.5%). The 90-day mortality rate was 0.9% (n=5). Using 2 cutoffs (182%, 240%), vWF-Ag was found to be an independent predictive factor for PHLF grade B/C that remained statistically significant upon multivariable analysis. The combination of preoperative APRI+ALBI and vWF-Ag increased the positive predictive value to 27.9% for PHLF grade B/C in the APRI+ALBI high and vWF-Ag high group. Incorporation of vWF-Ag into the established APRI+ALBI-based multivariable model revealed a superior AUC of 0.772 for PHLF risk stratification and was successfully validated in an independent cohort (AUC=0.834). The combination of vWF-Ag with APRI+ALBI demonstrates a favorable predictive potential for PHLF risk assessment. We provide 2 pathways for clinical assessment: (1) a cutoff-based system and (2) a more complex multivariable model that can be calculated in a specifically designed smartphone application.
Comparative efficacy of systemic therapies in malignant insulinoma
Koch, Regina M. , Vella, Adrian, Shah, Pankaj, Hobday, Timothy J. , Sonbol, Mohamed Bassam, Starr, Jason S. , Eiring, Rachel A. , McKenzie, Travis J. , Sada, Alaa , Koch, Regina , Starr, Jason , Gudmundsdottir, Hallbera , Eiring, Rachel A , McGarrah, Patrick W. , Shah, Pankaj, Starlinger, Patrick , Gudmundsdottir, Hallbera , Hálfdánarson, Þorvarður R.

Mayo Clinic

Endocrine-Related Cancer | May 29, 2025 | Volume: 32 | Issue: 6 | Pages: No page available

10.1530/erc-25-0091 | PMID 40439997 Get It

Abstract Malignant insulinomas are rare pancreatic neuroendocrine tumors characterized by excessive insulin secretion and a high propensity for metastasis, leading to challenging management. This study retrospectively analyzed 57 patients treated for malignant insulinoma at Mayo Clinic sites between 1992 and 2024, focusing on the efficacy of systemic therapies in improving hypoglycemic control and survival outcomes. The most commonly used therapies included somatostatin analogs (SSA), everolimus, capecitabine-temozolomide (CAPTEM), and peptide receptor radionuclide therapy (PRRT). PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%). SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively. Overall survival (OS) was longest with SSA at 84.67 months, followed by CAPTEM at 81.67 months and everolimus at 74.07 months. PRRT demonstrated a median OS of 49.73 months. In contrast, chemotherapy and streptozocin-based therapies had significantly shorter OS times of 15.23 and 8.35 months, respectively. These findings highlight significant variability in systemic therapy efficacy for malignant insulinoma, with PRRT emerging as a promising treatment for refractory hypoglycemia and long survival. Cox regression analysis identified primary tumor resection and a history of benign insulinoma as associated with longer OS. Optimal sequencing of therapies remains unclear, and individualized treatment plans based on hypoglycemic burden and tumor characteristics are critical for improving survival and quality of life in these patients.